Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab vs chemotherapy in second-line advanced esophageal cancer
CTR20160588Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in esophageal cancer, gastroesophageal junction adenocarcinoma, sponsored by Merck & Co.. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20160588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160588.